Masaoka III期伴大血管受累胸腺上皮肿瘤的手术切除:欧洲胸外科医师学会胸腺数据库回顾性多中心分析
该研究基于欧洲胸外科医师学会胸腺数据库,回顾性分析2001至2017年65例Masaoka III期伴大血管受累胸腺上皮肿瘤的手术结局。大血管以腔静脉或无名静脉为主(72.3%),术后心肺并发症11例(16.9%)。胸腺癌复发风险增高(HR=3.59,95%CI:1.66-7.78,P=0.001),总体生存满意,作者认为应争取完全切除。
要点
- 65例III期伴大血管受累胸腺上皮肿瘤患者接受手术,术后心肺并发症11例(16.9%)。
- 胸腺癌是无病生存的独立不良因素(HR=3.59,95%CI:1.66-7.78,P=0.001)。
- 总体生存率1、3、5、10年分别为0.86、0.84、0.81、0.53,切缘状态及胸腺癌与胸腺瘤间无显著差异。
核心结论
- III期伴大血管受累胸腺上皮肿瘤的手术治疗临床结局满意,作者认为可增加处理此类复杂手术的信心,应实现完全切除,即使需要广泛血管重建。
研究设计与样本
- 观察性多中心回顾性队列研究,数据来自欧洲胸外科医师学会胸腺数据库并补充变量,纳入标准为Masaoka-Koga III期胸腺上皮肿瘤、根治性手术意图、临床或病理大血管受累、影像学怀疑或术中诊断。
- 共纳入2001年至2017年接受手术的65例患者。
主要发现
- 胸腺瘤与胸腺癌患者在人口学和临床特征上无差异。
- 处理的大血管以腔静脉或无名静脉为主(72.3%)。
- 术后心肺并发症11例(16.9%),血管狭窄3例(4.6%)。
- 多变量Cox分析显示胸腺癌复发风险增高(HR=3.59,95%CI:1.66-7.78,P=0.001)。
- 1、3、5、10年总体生存率分别为0.86、0.84、0.81、0.53;按切除状态及胸腺瘤与胸腺癌比较,总体生存无显著差异。
临床怎么用
- 作者认为应实现完全切除,即使需要广泛血管重建。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to analyse the outcomes of an international cohort of patients affected by Masaoka stage III thymic epithelial tumours with vascular involvement and treated by surgery. METHODS: Study design was the observational multicentre retrospective cohort study. Data were extracted from the European Society of Thoracic Surgeons thymic database; additional variables were collected. Inclusion criteria were as follows: stage III (Masaoka-Koga) thymic epithelial tumours; surgery with radical intention; clinical or pathological great vessels involvement; and radiologically suspected or diagnosed intraoperatively. Outcome items were analysed. RESULTS: Sixty-five patients submitted to surgery from 2001 to 2017 fulfilled inclusion criteria. Thymoma and thymic carcinoma patients did not differ for demographics and clinical characteristics. The majority of great vessel treated were superior vena cava or innominate veins (72.3%). Eleven patients (16.9%) had postoperative cardiopulmonary complications; vascular stenosis was observed in 3 patients (4.6%). The multivariable Cox analysis for disease-free survival showed an increased hazard of recurrence for thymic carcinoma (hazard ratio = 3.59; 95% confidence interval: 1.66-7.78, P = 0.001). The 1-, 3-, 5- and 10-year overall survival rates were 0.86, 0.84, 0.81, and 0.53, respectively. There was no significant difference in overall survival according to resection status or between thymoma and thimic carcinoma. The univariable Cox regression model did not show an increased hazard of death for myasthenic patients considering all resection status and for patients who received neoadjuvant therapy. CONCLUSIONS: We observed that clinical outcomes of patients treated for stage III thymic epithelial tumours with vascular involvement are satisfactory suggesting to increase the confidence in dealing with these complex surgeries. Complete resection should be achieved, even though extensive vascular reconstructions are required.
引用
- Mendogni P, Toker A, Moser B, et al. Surgical resection of Masaoka stage III thymic epithelial tumours with great vessels involvement: a retrospective multicentric analysis from the European Society of Thoracic Surgeons thymic database. Eur J Cardiothorac Surg. 2022. PMID: 35084028. doi:10.1093/ejcts/ezac021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。